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Abstract
Background: The prevalence of sleep disorders increases with age. Sleep disorders may have serious health
implications and may be related to serious underlying diseases. Many older people use hypnotics, like
benzodiazepines, although these medications have serious side effects and often lead to habituation.
Acetaminophen is one of the most frequently used off-label drugs for sleep disorders, although little is known
about its effects. Our objective is to investigate whether acetaminophen is effective in treating self-reported sleep
disorders in older people.
Methods/Design: Participants, aged 65 years or older (n = 150), who have sleep disorders will be randomized for
treatment with either acetaminophen 1000 mg or placebo, once daily at bedtime in a double-blind design. Eligible
patients should be able to give informed consent, should not be cognitively impaired (Minimal Mental State
Examination (MMSE) score ≥ 20), should not have pain, and should not use acetaminophen on a regular basis
because of pain complaints. The study will take three weeks to complete. During these three weeks, the participants
register their sleep behavior in a sleep diary. The participants will use the study medication during the second and
third week. The primary endpoint will be the self-reported sleep disorders at the end of week three, as measured
by means of the Insomnia Severity Index (ISI). To validate these subjective sleep parameters against objectively
measured indices of the sleep-wake pattern, we will measure the periods of wakefulness and sleep in a subgroup
of participants, using an actigraph worn on the wrist during the entire study period.
Discussion: The proposed study will contribute to our knowledge about the treatment of sleep disorders in an
older population. There is a need for treatments for sleep disorders without serious adverse effects. Acetaminophen
might be a simple and inexpensive alternative for the regimes that are currently used with older people.
Trial registration: The Netherlands National Trial Register NTR2747.
Keywords: Acetaminophen, Geriatrics, Protocol, RCT, Sleep
* Correspondence: e.m.vandeglind@amc.nl
1Department of Internal Medicine, Geriatrics Section, Academic Medical
Center, P.O. Box 22660, Amsterdam 1100 DD, The Netherlands
2Dutch Cochrane Centre, Academic Medical Center, University of
Amsterdam, Amsterdam, The Netherlands
Full list of author information is available at the end of the article
TRIALS
© 2014 van de Glind et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
van de Glind et al. Trials 2014, 15:10
http://www.trialsjournal.com/content/15/1/10
Background
The prevalence of sleep disorders is high in older sub-
jects. In the Established Populations for Epidemiologic
Studies of the Elderly (EPESE) study, involving 9,282
community-dwelling persons aged 65 and older, 50% re-
ported sleep complaints, of which 25% had insomnia [1].
In a study of older patients in 11 primary care practices
(n = 1503), the most commonly reported sleep-related
complaints were difficulty sleeping (45%), snoring (33.3%),
and excessive daytime sleepiness (27.1%) [2]. Subjects with
insomnia report a negative impact on quality of life [3].
There are various hypotheses as to why older persons
suffer from sleep disorders. Single or multiple medical
problems, such as depression, cardiovascular diseases,
and pulmonary problems can interfere with a good
night’s rest. In addition, older people often use medica-
tion that causes insomnia, for example beta blockers and
psychopharmacological drugs. Only a minority of older
people suffer from primary insomnia [4].
The best treatment for sleep disorders remains a topic
of discussion. There is evidence for a positive effect of
cognitive behavioral interventions for sleep disorders in
older people [5,6], but these are time-consuming and
dependent on patient motivation. Some authors state
that bright light therapy might help, especially in the
case of a dysregulation of the circadian rhythm, but as
yet there have been no randomized trials [7]. There is a
lack of evidence from well-designed trials of the effect-
iveness of physical exercise for the treatment of sleep
problems in healthy older people [8]. The most common
way of treating sleep disorders is the pharmacological
approach [9]. Many older people use a sedative benzodi-
azepine as a hypnotic, although they are at risk of harm-
ful side effects because of age-related pharmacodynamic
and pharmacokinetic changes [10]. Adverse events, such
as falling [11,12], cognitive impairment [13], and drug
dependence [14], and even an increased risk of death
[15] are reported. Considering the health impact, the
complexity and the high prevalence, sleep disorders are
an important area of investigation and simple treatments
with fewer side effects are urgently needed.
In geriatric clinical practice, we have noticed that older
patients use acetaminophen for sleep problems without
having underlying pain complaints. In a survey of 176 older
people, 48% stated that they used nonprescription products
for sleeping problems. Of the individuals who had used a
nonprescription product, 19% used acetaminophen [16].
Although we did not find any trials or observational studies
in the literature that report the effect of acetaminophen on
sleep disorders, there are some ideas as to why this medi-
cation might have a positive effect. People who sleep better
on acetaminophen may have unrecognized pain com-
plaints. Another possible hypothesis is that acetaminophen,
after metabolization in the brain, reinforces the activity of
the cannabinoid receptors, which in turn reinforce the ac-
tivity of the serotonergic system [17,18]. Also, there may be
a relationship with body temperature [19], or its purported
effect could be mainly placebo.
This paper describes the design of the study named
ASLEEP (Acetaminophen for SLEep Problems in Elderly
Patients), a trial currently in progress. The aim of this
trial is to investigate whether acetaminophen has an
effect on self-reported sleep disorders in older people, as
measured by a score on a validated sleep questionnaire,
the Insomnia Severity Index (ISI) [20]. Also, to validate
the subjective sleep parameters against objectively mea-
sured indices of the sleep-wake pattern, we aim to study
the effects of acetaminophen on periods of wakefulness
and sleep, as measured by actigraphy in a subgroup of
our participants [21].
Methods/Design
This study is a randomized, placebo-controlled, double-
blind, national, multicenter study with a duration of three
weeks. This study will be carried out in three teaching
hospitals in the Netherlands: the Academic Medical Cen-
ter, the Gelre Hospitals, and the Slotervaart Hospital. The
study population will consist of people aged 65 years and
older suffering from sleep disorders, defined as one or
more of the following symptoms: difficulty falling asleep,
difficulty maintaining sleep or early awakenings without
being able to fall asleep again, with a frequency of at least
three nights a week, during at least three consecutive
weeks [22]. Participants may be patients that visit one of
the participating hospitals’ outpatient clinics, or they may
be subjects who are recruited after advertising in local
newspapers. The visitors of the outpatient clinic will be
enrolled during their visit; the people who respond to the
advertisements will be invited to come to one of the par-
ticipating hospitals for enrollment.
Eligible patients should have a score of five points or
more on the Pittsburgh Sleep Quality Index (PSQI) [23].
This is a validated instrument that assesses sleep quality
and disturbances over a 1-month time interval. A global
PSQI score greater than 5 yielded a diagnostic sensitiv-
ity of 89.6% and specificity of 86.5% in distinguishing
good and poor sleepers [23]. Further inclusion criteria
are: a score of 20 points or more on the Minimal Mental
State Examination (MMSE) [24] and participants must
be willing and medically able to receive therapy accord-
ing to the protocol for the duration of the study. In
addition, participants must be able to give informed
consent themselves.
Exclusion criteria are the inability to speak, understand
or write Dutch; the inability to follow the study proce-
dures, as assessed by the researcher; alcohol intake of
more than four units daily; the concomitant use of acet-
aminophen (>1000 mg daily); pain complaints resulting
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in a pain score of 6 or higher on a visual analog scale;
impaired liver function; suicidal tendencies; and partici-
pation in other sleep trials. In addition, patients with a
life expectancy of less than three months, according to
the attending physician, or with a sleep problem due to
a medical or somatic reason (a suspicion of obstructive
sleep apnea syndrome, restless legs, delirium, or a de-
pression necessitating antidepressants) are excluded.
Demographic data, medical history, and medication
use are recorded at baseline. The cognitive status is
assessed with the MMSE [24] and functional status is
assessed with the Katz-15 Activities of Daily Living index
[25]. The severity and number of comorbidities is scored
with the Charlson comorbidity index [26]. Possible con-
founding factors, like the use of comedication, other
sleeping pills, and the use of alcohol and coffee are regis-
tered for all patients.
During the first week, participants only register their
sleep patterns. In the second and third weeks, they also
take either 1000 mg acetaminophen in two tablets of
500 mg each, or two tablets of an exact matching
placebo, once per day at bedtime. Study medication is
packaged in small bottles labeled according to Good
Manufacturing Procedure guidelines. The medication is
provided in sequentially numbered containers according
to the randomization list. In the sleep diary, patients
register if they had taken the study medication the night
before.
Participants are allowed to continue their own pre-
scriptions, including their sleeping pills. They are asked
not to use newly prescribed sleeping pills. However,
sometimes it may happen that participants feel they can-
not sleep without using a sleeping pill in addition to the
study medication. If this happens, they are asked to
register this in the sleep dairy. Should it happen that
patients unexpectedly start a sleeping pill, they will no
longer receive the study medication, but data collection
will be continued.
Participants who need acetaminophen as a painkiller
during the study period will be prescribed this as usual
and will no longer receive the study medication. How-
ever, use of acetaminophen and not being able to stop
this medication during the study period is a reason for
exclusion. Also, patients who use acetaminophen as a
sleeping pill are asked to stop the medication for the
3-week study period, that is, both for the baseline data
collection and for the period that they use the study
medication. In the case of an unexpected need for
acetaminophen, despite the precautions taken in the en-
rollment procedure, participants should stop using the
study medication, because of a risk of overdose. How-
ever, the data collection will be continued in these cases
and we will perform both an intention-to-treat and a
per-protocol analysis.
The primary outcome measure will be the difference
in score on the ISI [6,27], as completed at the end of the
first and third weeks. Secondary outcomes will be the
use of extra sleeping pills and objective sleep parameters,
registered by means of an Actiwatch [21,28]. The Acti-
watch is a wristwatch-like device, worn on the nondomi-
nant hand, which records the motion for each epoch
(typically 30 to 60 seconds) for several weeks. A subgroup
of 25 patients enrolled in the Slotervaart Hospital will
wear the Actiwatch for 24 hours a day during the three-
week study period. In our trial, the Actiwatch Spectrum
device (Philips Respironics) will be used. Movements are
recorded in 1-minute epochs. The raw activity scores will
be translated to sleep-wake scores for each epoch, based
on standard algorithms, which are part of the proprietary
software that will be used to analyze the data. In addition
to this, all participants will record in a sleep diary the time
they get into and out of bed, the estimated time they fall
asleep and wake up in the morning and the number of
awakenings during the night. Furthermore, patients will
register a daily pain score by means of a 10 cm visual ana-
log scale. In addition, they will rate their sleep quality with
a score of 0 to 10. The combination of the actigraphy data
and the sleep diary will be used to estimate the following
sleeping and waking endpoints: total sleep time (minutes
sleep between bedtime and waking time), sleep efficiency
(percentage of time asleep while in bed), sleep onset
latency (minutes between bedtime and the first block of
consistent sleep scored epochs after bedtime), time awake
after sleep onset (minutes awake between sleep onset
and waking time), number of long wakeful episodes and
number of daytime nap episodes [21]. The Actiwatch
Spectrum has an ‘off wrist detection’ feature that will be
used to exclude daytime data if the participant takes the
actigraph off for more than 10% of the wake period [29].
The risks associated with this study consist of the pos-
sible adverse effects of acetaminophen. This is widely
used as an analgesic and has proved to be effective and
safe; therefore, the occurrence of side effects is not
likely. However, all adverse effects will be registered ac-
cording to Good Clinical Practice guidelines. During the
study, patients will be contacted by phone to evaluate
possible side effects.
An independent statistician provided a computer-
generalized randomization list, using block randomization
of ten participants per block. This list was stratified by
study center. The trial-pharmacist is the only one in pos-
session of the randomization list. The researcher who en-
rolled the patients is not aware of the assignment of the
participants. Subject enrollment started on 1 July 2011.
This study will be carried out in compliance with the
Helsinki Declaration. The Medical Ethics Committee of
the Academic Medical Center has approved the study
design, protocol, and informed consent procedures. The
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executive boards of the other participating centers, the
Slotervaart Hospital and Gelre Hospitals, have provided
local feasibility approval.
Power analysis
The primary endpoint will be a reduction in subjective
sleep disorders, as reflected in a lower score on the ISI
at the end of the third week compared with the score
after the first week. From the literature, a prevalence of
sleep disorders of 30% to 50% is reported. Group sam-
ple sizes of 75 per group achieve 80% power to detect a
difference of three points on the ISI between the null
hypothesis that both group mean differences are zero
and the alternative hypothesis that the mean difference
of the intervention group is three, with an assumed
group standard deviations of 6.5. This calculation is
based on data from a study in which a group of patients
with insomnia were treated with either eszopiclone or
placebo [30].
Statistics
Data will be primarily analyzed according to the intention-
to-treat principle. The outcome measures will be tested by
using t tests and Mann–Whitney tests for continuous
variables and by using chi-squared tests for categorical
outcomes. The data from the actigraphy and the sleep
diary will be analyzed as continuous variables, either with
an independent t test or with a Wilcoxon rank-sum test.
We will perform a subgroup analysis for patients using
sleeping pills at baseline and those who do not. If needed,
we will adjust for the use of add-on sleeping pills. Analyses
will be performed with the program Statistical Package for
the Social Sciences (SPSS) version 18.
Discussion
Sleep disorders are a major problem in older people,
and are associated with comorbidities and high costs.
To achieve good external validity, we intend to include
patients with all comorbidities and applied minimal
exclusion criteria. Older patients are often excluded
from clinical trials [31,32]. An additional benefit of this
research, which focuses on older patients, may be an
insight into the challenges and methods for performing
research with older patients. The proposed study will
contribute to our knowledge about the treatment of
sleep disorders in an older population by providing an
alternative for the traditional hypnotics. There is a
need for treatments for sleep disorders without serious
adverse effects. Acetaminophen could potentially fill
this gap, as it may be a promising simple and cheap
alternative for regimes that are currently used with
older people.
Trial status
The ASLEEP trial is currently in progress; patient
recruitment started on 1 July 2011 and was finished in
July 2013.
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